Aculys Pharma Names Hidemasa Tanigaki as CEO

Aculys Pharma Inc., a clinical-stage biopharmaceutical company, has appointed Hidemasa Tanigaki as Chief Executive Officer (CEO) and Representative Director, effective March 29th.
 
Tanigaki has been a leader in the pharmaceutical sector for over 30 years. He began his journey with Takeda Pharmaceutical Company in 1992 and held numerous key positions throughout his tenure with the company. After starting his career as a medical rep, he was later involved in the successful launch of multiple products. From 2015, he was global lead in Boston for the oncology business strategy. Upon his return to Japan, he served as Sales Director for Specialty Pharma and the Head of Rare Hematology, before assuming the role of President and Representative Director of Nihon Pharmaceutical Co., Ltd. in 2021. He then led the Gastrointestinal Disease Business Unit at Takeda.
 
Tanigaki said: “I am thrilled to join Aculys which focuses on addressing today’s drug lag/drug loss with an utmost sense of urgency. I believe the Aculys’ pipeline carries great potential to transform the lives of patients. I look forward to working with the team to deliver such products to those in need as quickly as possible.”
 
BT Slingsby, Executive Chairperson of Aculys, added: “The Aculys Board warmly welcomes Hidemasa as the new CEO of Aculys. We believe his impressive track record and experience in the pharmaceutical sector make him an ideal leader to take the team and assets toward commercialization. We are confident he will continue to position the Company as a leading biopharma in the field of neurological and psychiatric disorders, executing Aculys’ clinical, commercial, and financial strategy.”
 
Takeshi Takahashi will step down as the interim CEO and remain a Board Member.